More commercial AID systems. What do the trials tell us?
As many will be aware, at ADA Scientific Sessions this week, Medtronic announced the the outcomes of a number of trials of the 780G, including […]
Uncategorized
#Libre – An example of ongoing variance within Diabetes care, looking at London area where this wasn’t supposed to happen…
A review of the variation across London in prescribing Libre.
#Fiasp and #OpenAPS – is this what we’ve been waiting for? A week in the life….
I’ll cut to the chase. This has been one of the more interesting weeks in my life with diabetes. There aren’t many occasions when you […]
Are we living in the past? Good reasons why achieving the NICE Target Hba1C with the available NHS tools is tough…
As many people (but let’s face it, not all) are aware, the NICE target for Hba1C level is 6.5% as this is the point at […]
It’s EASD time again, and there’s a lot going down at the 52nd Annual Meeting
Gutted as I and many others of the GBDOC are to not be at the European Association for the Study of Diabetes (EASD) annual meeting […]
The great #gbdoc CGM debate – an alternative approach to NHS funding…
Following yesterday’s NNF conference on Continuous Glucose Monitoring (CGM) and the ensuing Twitter debate that frequently happens with these types of event, I gave some […]